Law360, Wilmington (May 04, 2012, 3:29 PM ET) -- A Gen-Probe Inc. shareholder launched a class action in Delaware court on Friday challenging Hologic Inc.'s planned $3.7 billion buyout of the diagnostic-testing company, calling the offer opportunistic and inadequate.
In a Delaware Chancery Court complaint, shareholder Timothy Coyne alleged that Gen-Probe’s directors breached their duty to investors by signing off on the $82.75-per-share deal. He said the buyout comes during a lull in the San Diego-based company’s stock price that does not reflect its recent success and potential for growth.
In fact, the deal was...
Gen-Probe Shareholder Aims To Block $3.7B Hologic Deal
To view the full article, take a free trial now.
